NEW YORK (GenomeWeb News) — Clinical proteomics company Correlogic Systems today said it has renewed a research collaboration and signed a new agreement with Japanese company Mitsui.
The new deal extends a relationship begun in 2004 when the companies signed an exploratory agreement to use Correlogic's pattern-recognition approach and technology to detect ovarian cancer in Japanese women.
Correlogic said the new agreement marks the conclusion of that "mini-trial" and said the two companies will now continue to develop pattern-recognition tests for ovarian and other cancers that are prevalent in Japan.
Japanese pharmaceutical company Quintiles Japan will help the companies select samples and conduct more trials.
Financial details of the new agreement were not disclosed.